Atrium Therapeutics, Inc. Common Stock RNA
$7.67
-1.92%
at last close
Market Cap$133.77 million
P/E Ratio—
Div Yield—
Volume191.0K
52-Week Range
$7.54$73.06
Analyst Ratings
- Consensus
- Moderate Buy — 5 Buy · 7 Hold · 0 Sell (12 analysts)
- Avg. Price Target
- $49.27 (+542.4% upside)
Key Stats
- Today's Range
- $7.67 – $8.06
- 50-Day Range
- $7.54 – $14.68
- 52-Week Range
- $7.54 – $73.06
- Volume
- 191K shs
- Average Volume
- 394K shs
- Market Cap
- $133.77 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Related Stocks
Compare head-to-head: RNA vs LLY·RNA vs JNJ·RNA vs ABBV·RNA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.